Your browser doesn't support javascript.
loading
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.
Novotny, J F; Cogswell, J; Inzunza, H; Harbison, C; Horak, C; Averbuch, S.
Affiliation
  • Novotny JF; Bristol-Myers Squibb, Princeton, USA james.novotnyjr@bms.com.
  • Cogswell J; Bristol-Myers Squibb, Princeton, USA.
  • Inzunza H; Bristol-Myers Squibb, Princeton, USA.
  • Harbison C; Bristol-Myers Squibb, Princeton, USA.
  • Horak C; Bristol-Myers Squibb, Princeton, USA.
  • Averbuch S; Bristol-Myers Squibb, Princeton, USA.
Ann Oncol ; 27(10): 1966-9, 2016 10.
Article in En | MEDLINE | ID: mdl-27502705
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B7-H1 Antigen / Programmed Cell Death 1 Receptor / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B7-H1 Antigen / Programmed Cell Death 1 Receptor / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Affiliation country: United States